FDA grants TGR1202 orphan drug designation for Chronic Lymphocytic Leukemia

Release Date: 17-Oct-2016

T.G therapeutics, a bio pharmaceutical company based on developing drugs and effective treatments for B-cell malignancies and autoimmune diseases, declares it’s oral, next generation PI3K Delta inhibitor, TGR 1202,  as an orphan drug, approved by Food and Drug Association (FDA) for the treatment of patients with Chronic Lymphocytic Leukemia (CLL).  Presently, TGR 1202 is being examined for UNITY-CLL Phase 3 Trial for patients with both frontline and previously treated CLL.


Chronic lymphocytic leukemia is a kind of cancer caused by formation of a number of lymphocytes by bone marrow. CLL has been recorded to affect mostly adults, during or after their middle age. Approximately 20,000 people are diagnosed with CLL United States every year.


For Orphan Drug Clinical Insight Reports Contact: neeraj@kuickresearch.com

Need custom market research solution? We can help you with that too.